JP2014515751A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515751A5
JP2014515751A5 JP2014505470A JP2014505470A JP2014515751A5 JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5 JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5
Authority
JP
Japan
Prior art keywords
seq
grf analog
ala
grf
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505470A
Other languages
English (en)
Japanese (ja)
Other versions
JP6113144B2 (ja
JP2014515751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/050242 external-priority patent/WO2012142706A1/en
Publication of JP2014515751A publication Critical patent/JP2014515751A/ja
Publication of JP2014515751A5 publication Critical patent/JP2014515751A5/ja
Application granted granted Critical
Publication of JP6113144B2 publication Critical patent/JP6113144B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505470A 2011-04-21 2012-04-17 成長ホルモン放出因子(grf)類似体およびその使用 Expired - Fee Related JP6113144B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477775P 2011-04-21 2011-04-21
US61/477,775 2011-04-21
PCT/CA2012/050242 WO2012142706A1 (en) 2011-04-21 2012-04-17 Growth hormone releasing factor (grf) analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2014515751A JP2014515751A (ja) 2014-07-03
JP2014515751A5 true JP2014515751A5 (enExample) 2015-06-11
JP6113144B2 JP6113144B2 (ja) 2017-04-12

Family

ID=47021786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505470A Expired - Fee Related JP6113144B2 (ja) 2011-04-21 2012-04-17 成長ホルモン放出因子(grf)類似体およびその使用

Country Status (10)

Country Link
US (1) US8361964B2 (enExample)
EP (1) EP2699591A4 (enExample)
JP (1) JP6113144B2 (enExample)
KR (1) KR20140027284A (enExample)
CN (1) CN103547591A (enExample)
AR (1) AR087727A1 (enExample)
BR (1) BR112013027150A2 (enExample)
CA (1) CA2833434A1 (enExample)
MX (1) MX2013012259A (enExample)
WO (1) WO2012142706A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
SG11201808880PA (en) 2016-04-19 2018-11-29 Griffon Pharmaceuticals Inc Pegylated bioactive peptides and uses thereof
IL298991A (en) * 2020-07-05 2023-02-01 Theratechnologies Inc Low-dose pharmaceutical preparations of GHRH analogs and their uses

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4617149A (en) 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4801456A (en) 1987-07-09 1989-01-31 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
ATE106895T1 (de) * 1987-09-18 1994-06-15 Hoffmann La Roche Zyklische grf-analoga.
CA2040649A1 (en) * 1990-04-24 1991-10-25 Gerald S. Brooke Growth hormone releasing factor analogs
EP0542937A1 (en) 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
JPH11503454A (ja) 1995-04-14 1999-03-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 成長ホルモン放出因子の類似体
ES2163020T3 (es) 1995-05-26 2002-01-16 Theratechnologies Inc Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
AU9558901A (en) 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
EA006484B1 (ru) 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
PT2062914E (pt) * 2001-06-08 2014-07-18 Ipsen Pharma Sas Análogos quiméricos de somatostatina-dopamina
MXPA05002991A (es) 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
AU2004281084B2 (en) 2003-10-20 2010-08-12 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
JP2008516994A (ja) 2004-10-20 2008-05-22 セラテクノロジーズ、インコーポレイテッド 成長ホルモン分泌促進因子およびその使用
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
WO2010121352A1 (en) 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy

Similar Documents

Publication Publication Date Title
JP2013515057A5 (enExample)
IL262805B1 (en) CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death
JP2013515055A5 (enExample)
TWI374030B (en) Use of melanocortins to treat insulin sensitivity
JP2011526886A5 (enExample)
FI3482765T3 (fi) Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi
JP2013522311A5 (enExample)
BR122020011001B1 (pt) Peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos
JP2011511753A5 (enExample)
JP2005524648A5 (enExample)
JP2012500001A5 (enExample)
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP2013518057A5 (enExample)
JP2007509984A5 (enExample)
JP2013517307A5 (enExample)
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
JP2004504406A5 (enExample)
JP2014050390A5 (enExample)
JP2008530245A5 (enExample)
JP2010529957A5 (enExample)
JP2009191078A5 (enExample)
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2014530868A5 (enExample)
JP2019533722A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение